Development of Lanzyme as the Potential Enzyme Replacement Therapy Drug for Fabry Disease

Development of Lanzyme as the Potential Enzyme Replacement Therapy Drug for Fabry Disease

Fabry disease (FD) is a progressive multisystemic disease characterized by lysosomal enzyme deficiency. Enzyme replacement therapy (ERT) is one of the most significant advancements and breakthroughs in treating FD. However, limited resources and the high cost of ERT might prevent patients from recei...

Full description

Bibliographic Details
Main Authors: Mulan Deng, Hongyu Zhou, Zhicheng Liang, Zhaoyang Li, Yanping Wang, Wanyi Guo, April Yuanyi Zhao, Fanghong Li, Yunping Mu, Allan Zijian Zhao
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Biomolecules
Subjects:
lysosomal storage disorders (LSDs)
recombinant human α-galactosidase A (rhα-Gal A)
Fabry disease (FD)
enzyme replacement therapy (ERT)
globotriaosylceramide (Gb3)
Lanzyme
Online Access:https://www.mdpi.com/2218-273X/13/1/53

Internet

https://www.mdpi.com/2218-273X/13/1/53

Similar Items